Zelboraf Approved for Use in Erdheim-Chester Disease

Share this content:
Zelboraf Approved for Use in Erdheim-Chester Disease
Zelboraf Approved for Use in Erdheim-Chester Disease

WEDNESDAY, Nov. 8, 2017 (HealthDay News) -- Zelboraf (vemurafenib) has been approved by the U.S. Food and Drug Administration as the first drug to treat certain adults patients with Erdheim-Chester disease (ECD).

The efficacy of Zelboraf, a kinase inhibitor, was studied in 22 patients with BRAF-V600-mutation positive ECD. Fifty percent (11 patients) experienced a partial response and 4.5 percent (1 patient) experienced a complete response.

The most common side effects include arthralgia, rash, alopecia, fatigue, prolonged QT interval, and papilloma, the FDA said in a news release. Less common but more severe adverse reactions could include development of other cancers, severe skin reactions, hepatotoxicity, and kidney failure. The drug is contraindicated for pregnant women because it could harm a developing fetus, the FDA said.

"This product was first approved in 2011 to treat certain patients with melanoma that harbor the BRAF V600E mutation, and we are now bringing the therapy to patients with a rare cancer with no approved therapies," Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence, said in a statement.

The drug is produced by the Swiss pharmaceutical firm Hoffman-LaRoche.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC Issues Warning on Contaminated Raw Milk

CDC Issues Warning on Contaminated Raw Milk

Case of New Jersey woman becoming ill after drinking raw milk from Udder Milk company

Cerebral Morphometric Changes Discriminate ADHD, Controls

Cerebral Morphometric Changes Discriminate ADHD, Controls

Alterations discern ADHD-I, ADHD-C, with discriminating features located in DMN, insular cortex

Baby Boomers Have Increased Risk of Rx Opioid Overdose Death

Baby Boomers Have Increased Risk of Rx Opioid ...

In addition, those born from 1947 to 1964 and 1979 to 1992 have increased risk of heroin overdose death

is free, fast, and customized just for you!

Already a member?

Sign In Now »